PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 04/4/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. OKYO, ITRM, DYAI, AADI, HOWL, IBIO, MDCX, IPSC, ALVR, and VRCAShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include OKYO Pharma (OKYO), Iterum Therapeutics (ITRM), Dyadic International (DYAI), Aadi Bioscience (AADI), Werewolf Therapeutics (HOWL), iBio (IBIO), Medicus Pharma (MDCX), Century Therapeutics (IPSC), AlloVir (ALVR), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. OKYO Pharma Iterum Therapeutics Dyadic International Aadi Bioscience Werewolf Therapeutics iBio Medicus Pharma Century Therapeutics AlloVir Verrica Pharmaceuticals PHAXIAM Therapeutics (NASDAQ:PHXM) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking. Is PHXM or OKYO more profitable? Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A OKYO Pharma N/A N/A N/A Do institutionals and insiders believe in PHXM or OKYO? 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in PHXM or OKYO? OKYO Pharma received 10 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformPHAXIAM TherapeuticsN/AN/AOKYO PharmaOutperform Votes10100.00% Underperform VotesNo Votes Do analysts recommend PHXM or OKYO? OKYO Pharma has a consensus price target of $7.00, indicating a potential upside of 514.04%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts plainly believe OKYO Pharma is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, PHXM or OKYO? PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.32, indicating that its stock price is 132% less volatile than the S&P 500. Which has better earnings and valuation, PHXM or OKYO? PHAXIAM Therapeutics has higher revenue and earnings than OKYO Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM Therapeutics$32.66M0.32-$240KN/AN/AOKYO PharmaN/AN/A-$16.83MN/AN/A Does the media favor PHXM or OKYO? In the previous week, OKYO Pharma had 4 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 4 mentions for OKYO Pharma and 0 mentions for PHAXIAM Therapeutics. OKYO Pharma's average media sentiment score of 0.53 beat PHAXIAM Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Overall Sentiment PHAXIAM Therapeutics Neutral OKYO Pharma Positive SummaryOKYO Pharma beats PHAXIAM Therapeutics on 8 of the 11 factors compared between the two stocks. Remove Ads Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$117.00M$5.26B$7.12BDividend YieldN/A3.69%4.89%4.06%P/E RatioN/A3.1921.2617.49Price / Sales0.323,975.57355.3285.34Price / CashN/A13.0138.1834.64Price / Book0.3934.216.243.79Net Income-$240,000.00-$89.03M$3.21B$247.48M7 Day PerformanceN/A-4.73%-8.42%-6.75%1 Month PerformanceN/A58.27%-4.82%-11.50%1 Year PerformanceN/A78.76%2.58%-7.79% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049OKYOOKYO Pharma2.7657 of 5 stars$1.25+5.9%$7.00+460.0%-24.0%$42.30MN/A0.007ITRMIterum Therapeutics1.6288 of 5 stars$1.22+4.3%$5.00+309.8%-39.6%$42.19MN/A-0.9310DYAIDyadic International2.0021 of 5 stars$1.40+1.4%$6.00+328.6%-32.8%$42.13M$3.50M-6.097Gap DownAADIAadi Bioscience0.8844 of 5 stars$1.70-4.5%$1.67-2.0%-24.4%$41.99M$25.07M-0.7540Gap DownHOWLWerewolf Therapeutics1.7519 of 5 stars$0.91+4.8%$9.00+886.4%-88.4%$40.90M$1.89M-0.6040IBIOiBio1.6549 of 5 stars$4.12+5.4%$4.30+4.4%+29.3%$40.69M$375,000.000.00100Positive NewsGap DownMDCXMedicus PharmaN/A$3.40-14.1%$10.00+194.1%N/A$40.54MN/A0.00N/AEarnings ReportPositive NewsGap UpHigh Trading VolumeIPSCCentury Therapeutics1.9313 of 5 stars$0.47+4.0%$5.00+964.5%-87.9%$40.42M$6.59M-0.25170Analyst ForecastAnalyst RevisionGap DownALVRAlloVir1.7887 of 5 stars$8.00-0.4%N/A-57.7%$40.34MN/A-0.40110VRCAVerrica Pharmaceuticals3.6866 of 5 stars$0.44+4.2%$9.50+2,067.0%-91.7%$40.24M$7.57M-0.2440Gap Down Remove Ads Related Companies and Tools Related Companies OKYO Pharma Competitors Iterum Therapeutics Competitors Dyadic International Competitors Aadi Bioscience Competitors Werewolf Therapeutics Competitors iBio Competitors Medicus Pharma Competitors Century Therapeutics Competitors AlloVir Competitors Verrica Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHXM Stock Free PHXM Stock Alerts